About Genprex
Genprex (NASDAQ:GNPX) is a clinical-stage gene therapy company deeply rooted in developing treatments for cancer and diabetes. Through groundbreaking research and innovative technology, Genprex is on the forefront of creating gene therapies that could potentially transform patient outcomes. The company's operations are focused on advancing its proprietary platform technologies, including Oncoprex™ immunogene therapy for non-small cell lung cancer. A pivotal part of their mission is to leap beyond traditional treatments, harnessing the power of gene therapy to unlock new possibilities for patients around the globe. With a passionate commitment to science and health, Genprex aims to achieve significant milestones in medicine and offer new hope to individuals battling these complex diseases.
Snapshot
Operations
Products and/or services of Genprex
- Oncoprex immunogene therapy, targeting non-small cell lung cancer using tumor suppressor gene therapy.
- REQORSA, a gene therapy for lung cancer in combination with targeted therapies and immunotherapies.
- GPX-002, gene therapy for diabetes, aiming to regenerate insulin-producing beta cells.
- Partnership initiatives to enhance gene therapy delivery platforms, improving efficiency and targeting.
- Collaborations with academic institutions for research in gene therapy for cancer treatment.
- Development of a proprietary non-viral delivery system, Nanoparticle Delivery System, for broad applications in gene therapy.
Genprex executive team
- Mr. Ryan M. Confer M.S.President, CEO, CFO & Director
- Dr. Mark S. Berger M.D.Chief Medical Officer
- Mr. David M. SchlossSenior Vice President of Human Resources
- Mr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & Licensing
- Dr. Suzanne Thornton-Jones Ph.D.Senior Vice President of Regulatory Affairs & Quality
- Ms. Celina LaneyChief of Staff
- Dr. Jack A. Roth F.A.C.S., M.D.Chairman of Scientific & Medical Advisory Board